Klaus Freeland, MD
Ophthalmology · Fort Riley, KSNPI 1407161771
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 91 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AbbVie at 26.1% of the total. 2025 is the largest year on record at $456, 9.8 times the $46 reported in 2019.
Across 91 payments — averaging $20.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$488
- Alcon$209
- Amgen$187
- Johnson & Johnson Surgical Vision, Inc.$180
- Kala Pharmaceuticals, Inc.$128
- Eyevance Pharmaceuticals LLC$105
- plus $573 from 14 others
What the payments were for
- Food & beverage$1,870100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 25 | $488 |
| Alcon | 11 | $209 |
| Amgen | 9 | $187 |
| Johnson & Johnson Surgical Vision, Inc. | 7 | $180 |
| Kala Pharmaceuticals, Inc. | 6 | $128 |
| Eyevance Pharmaceuticals LLC | 5 | $105 |
| Mallinckrodt Hospital Products Inc. | 4 | $74 |
| Bausch & Lomb Americas Inc. | 3 | $68 |
| Glaukos Corporation | 3 | $61 |
| Sight Sciences, Inc. | 3 | $59 |
| Aerie Pharmaceuticals, Inc. | 3 | $53 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $50 |
| Biotissue Holdings Inc. | 2 | $48 |
| Dompe US, Inc. | 1 | $29 |
| Astellas Pharma US Inc | 1 | $27 |
| Staar Surgical Company | 1 | $25 |
| Merz North America, Inc. | 1 | $22 |
| Oyster Point Pharma, Inc. | 1 | $22 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
| Rxsight Inc | 1 | $13 |
How this compares
$1,870 in reported general payments places this provider in the 55th percentile of 135 ophthalmology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 267 | $12,815 |
| Ketorolac Tromethamine | 244 | $6,951 |
| MoxifloxacinMoxifloxacin Hcl | 320 | $6,534 |
| Latanoprost | 458 | $6,459 |
| LumiganBimatoprost | 12 | $5,966 |
| Fluorometholone | 72 | $4,125 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 22 | $3,706 |
| Brimonidine Tartrate | 39 | $2,260 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 122 | $1,908 |
| Timolol Maleate | 122 | $1,609 |
| Difluprednate | 11 | $1,275 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 62 | $724 |
| ErythromycinErythromycin Base | 31 | $330 |
| Dorzolamide Hcl | 17 | $286 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan | $488 | $5,96612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 135 ophthalmology providers in Kansas.
Other ophthalmology in Fort Riley
- Aaron WoldFort Riley$2K
- Daniel DurrieOverland Park$974K
- John DoaneLeawood$496K
- John HunkelerOverland Park$218K
- Christopher PoleOverland Park$129K
- Blake CooperLenexa$100K
- Miranda BisharaPrairie Village$45K
- Jeff WongskhaluangOlathe$42K
- Michael EllisLenexa$38K
- Matthew SniegowskiLeawood$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.